Inventor profile of:

Jasper DINGEMANSE

City:

Allschwil

Country:

Switzerland

Published Applications:

13

Last publication date:

2025-09-11

Top Assignees for applications by Jasper DINGEMANSE

The entities that hold a legal rights for patent applications filed by inventor DINGEMANSE Jasper:

Recent patent applications by DINGEMANSE Jasper

Jasper DINGEMANSE from Allschwil, CH has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-09-11
US20250281463A1
Human necessities

DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST

#2 | 2023-04-27
US20230131600A1
Human necessities

DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST

#3 | 2023-01-05
US20230002365A1
Chemistry; metallurgy

Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol

#4 | 2021-12-30
US20210401811A1
Human necessities

DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST

#5 | 2021-02-25
US20210052555A1
Human necessities

Dosing regimen for a selective S1Preceptor agonist

#6 | 2019-10-24
US20190322657A1
Chemistry; metallurgy

Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol

#7 | 2019-05-23
US20190151292A1
Human necessities

Dosing regimen for a selective S1Preceptor agonist

#8 | 2018-05-31
US20180147188A9
Human necessities

Dosing regimen for a selective S1Preceptor agonist

#9 | 2017-11-09
US20170319555A1
Human necessities

Dosing regimen for a selective S1Preceptor agonist

#10 | 2015-09-24
US20150265580A1
Human necessities

Dosing regimen for a selective S1Preceptor agonist

#11 | 2014-10-23
US20140316140A1
Human necessities

Dosing regimen for a selective S1Pagonist

#12 | 2014-10-23
US20140315964A1
Human necessities

DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST

#13 | 2014-10-09
US20140303217A1
Human necessities

DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST

InventorID:

930952 ⎘